Critical Perspective in Right to Try - Preparing for the House Vote

Posted on 01/10/2018

A few weeks ago Early Access Care brought you the 2017 legislative summary of Expanded Access.  We summarized by saying “This may be the year for national Right to Try legislation.”  In today’s NEJM, Joffe and Fernandez Lynch1  presented critical perspective in preparation of the imminent House vote on Right to Try.  Their summary statement says it all: “Are we prepared to abandon the FDA’s gatekeeping role in favor of unfettered patient autonomy and market forces, risking precisely the problems that prompted Congress to grant the FDA its present authority?”  

Changes are on the horizon and Early Access Care assists pharmaceutical companies in the optimization of solutions for Expanded Access programs. Solutions for Pharmaceutical Companies

Reference:  1.  S. Joffe and H. Fernandez Lynch, NEJM Jan 10, 2018